KMT2A and leukemia: Klossowski et al. confirmed that the Menin-specific inhibitor MI-3454 inhibited cell proliferation and induced differentiation in primary patient samples with MLL translocations or NPM1 mutations and induced the remission or regression of leukemia in mouse models of MLL-rearranged or NPM1-mutated leukemia [96].